Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian approval for Myconostica's Aspergillus test

This article was originally published in Clinica

Executive Summary

Myconostica has been granted a licence by Health Canada to sell its MycAssay Aspergillus test there. The diagnostic detects Aspergillus DNA in lower respiratory tract samples, including those obtained by bronchoalveolar lavage, using real-time PCR, and can provide results in three hours when used with the company’s extraction system, MycXtra. Conventional methods can take up to 10 days. Aspergillus is a fungal infection that can cause potentially life-threatening pneumonia, particularly in immunocompromised people such as leukaemia and bone marrow cancer patients. Manchester, UK-based Myconostica CE marked the test for sale in Europe in October 2009 (www.clinica.co.uk, October 14 2009). Meanwhile, the firm has signed up Inverness Medical Canada, a subsidiary of Inverness Medical Innovations, as the exclusive distributor of its products in Canada.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel